Table 4.
Univariate analysis of factors affecting the prognosis in patients with DN
| Variables | Poor prognosis group (n=25) | Good prognosis group (n=101) | χ2 | P |
|---|---|---|---|---|
| Age (<50 years/≥50 years) | 10/15 | 48/53 | 0.457 | 0.499 |
| Sex (male/female) | 19/6 | 56/45 | 3.514 | 0.061 |
| Course of the disease (<9 years/≥9 years) | 8/17 | 37/64 | 0.187 | 0.665 |
| BMI (<24 kg/m2/≥24 kg/m2) | 13/12 | 46/55 | 0.335 | 0.563 |
| Hypertension (with/without) | 11/14 | 36/65 | 0.598 | 0.439 |
| IL-1β (<25 pg/mL/≥25 pg/mL) | 10/15 | 53/48 | 1.248 | 0.264 |
| hs-CRP (<16 mg/L/≥16 mg/L) | 8/17 | 59/42 | 5.616 | 0.018 |
| TNF-α (<49 pg/mL/≥49 pg/mL) | 7/18 | 59/42 | 7.433 | 0.006 |
| TGF-β1 (<196 pg/mL/≥196 pg/mL) | 14/11 | 42/59 | 1.687 | 0.194 |
| VEGF (<418 pg/mL/≥418 pg/mL) | 12/13 | 45/56 | 0.096 | 0.757 |
| Hcy (<28 μmol/L/≥28 μmol/L) | 13/12 | 56/45 | 0.096 | 0.757 |
| BUN (<10 mmol/L/≥10 mmol/L) | 10/15 | 67/34 | 5.849 | 0.016 |
| Cr (<85 mmol/L/≥85 mmol/L) | 13/12 | 48/53 | 0.161 | 0.689 |
| mAlb (<232 mg/24 h/≥232 mg/24 h) | 11/14 | 52/49 | 0.449 | 0.503 |
| Treatment modality (TEL/TEL + CTL) | 17/8 | 8/93 | 45.480 | <0.001 |
Note: DN, diabetic nephropathy; BMI, body mass index; TEL, telmisartan; CTL, calcitriol.